On March 18, 2026, Ernexa Therapeutics Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This situation arises from the company's recent reverse stock split, which has rendered it ineligible for the standard 180-day compliance period typically afforded to companies in such circumstances. As a result, Ernexa intends to request a hearing before the Nasdaq Hearing Panel, which will automatically stay any suspension or delisting action pending the hearing and any additional extension period granted by the Panel. The company plans to present its compliance strategy to regain adherence to the Minimum Bid Price Requirement. However, there are no guarantees that the Panel will grant a favorable decision or that the company's securities will remain listed on the Nasdaq Capital Market. This development is concerning for investors, as it may lead to significant liquidity issues and a potential loss of investor confidence.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.